WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Travis Kelce responds to Jana Kramer's claims he's a bad influence on girlfriend Taylor SwiftThe Masked Singer: Chrissy Metz reveals identity after performing as Poodle Moth in quarterfinalsThe REAL reason no one should have to pay for their prescriptionsBungalow wars! Downsizers are in bidding battles against young families as prices soarSouth Sudan mediation talks launched in Kenya with a hope of ending conflictNCAA removes cap on official recruiting visits in basketball to deal with unlimited transfersMaine man sentenced to 27 years in prison in New Year's Eve machete attack near Times SquareJodie Turner'Big Bear' on the prowl. Braves' Marcell Ozuna heading for another big yearWisconsin woman who argued she legally killed sex trafficker pleads guilty to homicide
1.8632s , 6497.5234375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Window news portal